Alpha v integrin receptor antagonists
CA 2373937 A1 · Owner: Hutchinson, John H. · Inventors: Hartman, George D.; Hutchinson, John H.; Wang, Jiabing
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel nonanoic acid derivatives their , synthesis, and their use as alphaV integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors alphaV beta3 and alphaV beta5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis and inhibiting vascular , restenosis, diabetic retinopathy macular degeneration, angiogenesis, atherosclerosis inflammation, inflammatory arthritis, viral disease cancer, and metastatic tumor growth.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 30, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 30, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 30, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.